WO2017203456A1 - Compositions topiques stables de luliconazole - Google Patents

Compositions topiques stables de luliconazole Download PDF

Info

Publication number
WO2017203456A1
WO2017203456A1 PCT/IB2017/053078 IB2017053078W WO2017203456A1 WO 2017203456 A1 WO2017203456 A1 WO 2017203456A1 IB 2017053078 W IB2017053078 W IB 2017053078W WO 2017203456 A1 WO2017203456 A1 WO 2017203456A1
Authority
WO
WIPO (PCT)
Prior art keywords
topical composition
stable topical
acid
composition
stable
Prior art date
Application number
PCT/IB2017/053078
Other languages
English (en)
Inventor
Ulhas Rameshchandra Dhuppad
Nitin Babulal Bhamre
Prashant Sarjerao GAIKWAD
Vivek Ramadasswami ALAI
Original Assignee
Glenmark Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Limited filed Critical Glenmark Pharmaceuticals Limited
Priority to BR112018074143-4A priority Critical patent/BR112018074143A2/pt
Priority to RU2018141796A priority patent/RU2018141796A/ru
Priority to MX2018014485A priority patent/MX2018014485A/es
Publication of WO2017203456A1 publication Critical patent/WO2017203456A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol.
  • the compositions are free of an aliphatic alcohol and a ketone.
  • Luliconazole is an imidazole antifungal that has been approved first in Japan for topical treatments of fungal infections. Luliconazole is represented by a structural formula (I)
  • Cream contains benzyl alcohol 1% w/w, butylated
  • hydroxytoluene cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben 0.14% w/w, polysorbate 60, propylene glycol, purified water, and sorbitan monostearate.
  • Lulifine 1% Cream is indicated for the treatment of cutaneous mycosis Tinea: Tinea pedis, tinea corporis and tinea cruris; Candidiasis: Intertrigo and interdigital erosion, Tinea versicolor.
  • Lulifin 1% Lotion in non-aqueous base contains 46% v/v ethanol IP, polyethylene glycol 400, medium-chain triglycerides, ethyl methyl ketone, phosphoric acid and ethanol and is indicated for cutaneous mycosis Tinea: Tinea pedis, tinea corporis and tinea cruris. Luliconazole is disclosed in International patent application publication no. WO9702821.
  • Japanese patent application publication no.JP2002114680 covers luliconazole composition containing butylated hydroxytoluene, cetostearyl alcohol, isopropyl myristate, medium-chain triglycerides, methylparaben, polysorbate 60, propylene glycol, purified water, and sorbitan monostearate.
  • International patent application publication no.WO2011155640 relates to luliconazole compositions comprising a polyhydric alcohol derivative.
  • International patent application publication no. WO2014042043 discloses luliconazole composition containing one or more of carboxylic acid and derivative thereof, ketone, phosphoric acid and derivative thereof, local anaesthetic, antihistamine, and POE-based non-ionic surfactant.
  • International patent application publication no. WO2007102242 discloses Luliconazole is dissolved in propylene carbonate solvent at a concentration of 0.1 to 40% by mass.
  • International patent application publication no. WO2007102241 relates to a composition of luliconazole and a-hydroxycarboxylic acid/salt.
  • International patent application publication no.s WO2014041708 and WO2014136282 relate to Specific crystal habit helps to improve the solubilization of the luliconazole.
  • WO2010117089 provide luliconazole composition comprising a higher ale. and/or a diester of a dibasic acid excluding a diester carbonate, and a polyoxyethylene alkyl ether and/or a polyoxyethylene alkenyl ether.
  • WO2007102242 discloses luliconazole composition comprising one or two or more members selected from among N-methyl-2-pyrrolidone, propylene carbonate, and crotamiton.
  • WO2015156219 describes pharmaceutical compositions containing a steroid and an antifungal agent.
  • WO2011024620 discloses pharmaceutical compositions of luliconazole with a ketone and a hydroxyalkylbenzene for excellent solubilization and suppressing stereo-isomerization of luliconazole.
  • International patent application publication no. WO2009031642 relates to an antifungal agent for external application 50-95 % by mass of an alcohol, and 0.1-35 % by mass of water and/or an anionic surfactant.
  • Excipient like alcohol may cause hydrolysis or the like to affect the stability of an active.
  • the compound may not be sufficiently dissolved and may be time-dependently precipitated when an alcohol amount is small, whereas an excess alcohol amount may impair the pharmaceutical acceptability.
  • the present invention discloses stable topical compositions comprising Miconazole wherein the compositions are free of an aliphatic alcohol and a ketone. Further the stable topical compositions of the present invention are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical compositions comprising Luliconazole. Further the present invention also relates to stable topical compositions comprising combination of luliconazole with a corticosteroid such as betamethasone or clobetasol.
  • a corticosteroid such as betamethasone or clobetasol.
  • the present invention relates to stable topical composition
  • luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain alcohol is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
  • the stable topical composition comprising
  • luliconazole of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of luliconazole, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the
  • the stable topical composition comprises one or more of 0.5% -2% of luliconazole, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%- 2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention may comprise from about 30%-95% by weight of one or more vehicles selected from diethanolamine lauryl slulphate, propylene glycol, purified water.
  • the present invention also provides stable topical composition comprising luliconazole in combination with a corticosteroid.
  • Steroids reduce inflammation of the skin, increases tissue infiltration of the antifungal agent.
  • the present invention relates to stable topical composition
  • luliconazole in combination with a corticosteroid wherein; the corticosteroid is selected from a group consisting of hydrocortisone, prednisolone, dexamethasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
  • the corticosteroid is beclomethasone dipropionate.
  • the corticosteroid is clobetasol propionate.
  • the present invention relates to a stable topical composition luliconazole and a corticosteroid wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • luliconazole and a corticosteroid wherein;
  • compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain triglyceride is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene and isopropyl myristate.
  • the stable topical composition comprising
  • luliconazole and a corticosteroid of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention is in the form of any of the dosage form such as gels, creams, ointments, lotions, shampoo, powders, suspensions and solutions.
  • the stable topical composition of the present invention is for use in treating fungal infections.
  • the present invention relates to method of treating fungal infections with stable topical composition of the invention.
  • the present invention relates to method of treating fungal infections using stable topical composition of the invention.
  • the present invention relates to stable topical compositions comprising Miconazole. Further the present invention also relates to stable topical compositions comprising combination of Miconazole with a corticosteroid such as betamethasone or clobetasol.
  • a corticosteroid such as betamethasone or clobetasol.
  • active means Miconazole or a corticosteroid or its salts, or some additional actives as described herein or combination thereof.
  • stable topical composition is used to refer to a pharmaceutical composition for application to body surfaces such as the skin or mucous membranes to treat ailments.
  • the composition may be in any of a range of dosage forms including but not limited to creams, foams, shampoos, powders, gels, lotions, patches, ointments, suspensions and solutions.
  • the stable topical composition may be epicutaneous, meaning that it is applied directly to the skin or mucosa.
  • the effect of the stable topical composition in the pharmacodynamics sense may be local and primarily address condition of the skin including either or both of the epidermis and underlying dermal layers and/or tissue such as muscles, bones, ligaments and internal organs covered by the skin rather than systemic, or be systemic or provide both local and systemic effects.
  • Stable topical may be local and primarily address condition of the skin including either or both of the epidermis and underlying dermal layers and/or tissue such as muscles, bones, ligaments and internal organs covered by the skin rather than systemic, or be systemic or provide both local and systemic effects.
  • compositions can be used for both stable topical and transdermal administration of substances.
  • luliconazole as used herein, unless mentioned otherwise mentioned, means 2(2E)-2-[(4R)-4-(2, 4-dichlorophenyl)-l, 3-dithiolan-2- ylidene]-2-imidazol-l-ylacetonitrile, hydrates, solvates or salts thereof.
  • corticosteroid includes hydrocortisone, prednisolone, dexamethasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
  • salt or “pharmaceutically acceptable salt” it means those salts and esters which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, and allergic response, commensurate with a reasonable benefit to risk ratio, and effective for their intended use.
  • Representative salts include the hydrochloride, furoate, hydrobromide, sulphate, bisulphate, acetate, oxalate, valerate, propionate, dipropionate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, mesylate, citrate, maleate, fumarate, succinate, tartrate, ascorbate, glucoheptonate, lactobionate, and lauryl sulphate salts.
  • % by weight means percentage w/w with respect to finished dosage form or stable topical composition.
  • the present invention relates to stable topical composition
  • luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • stable topical composition comprising luliconazole wherein; the compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain alcohol is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
  • the stable topical composition comprising
  • Miconazole of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%- 2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention may comprise from about 30%-95% by weight of one or more vehicles selected from diethanolamine lauryl sulphate, propylene glycol, purified water.
  • the present invention also provides stable topical composition comprising luliconazole in combination with a corticosteroid.
  • Steroids reduce inflammation of the skin, increases tissue infiltration of the antifungal agent.
  • the present invention relates to stable topical composition
  • luliconazole in combination with a corticosteroid
  • the corticosteroid is selected from a group consisting of hydrocortisone, prednisolone, dexamethasone, clobetasone, clobetasol, betamethasone, beclomethasone, mometasone or salts thereof.
  • the corticosteroid is beclomethasone dipropionate.
  • the corticosteroid is clobetasol propionate.
  • the present invention relates to a stable topical composition luliconazole and a corticosteroid wherein; the compositions are free of an aliphatic alcohol and a ketone.
  • the present invention relates to stable topical composition
  • luliconazole and a corticosteroid wherein;
  • compositions are free of an aliphatic alcohol and a ketone; and wherein the stable topical composition further comprises one or more pharmaceutical excipients selected from a group consisting of a medium chain triglyceride, a polyhydric alcohol, and an ester of a fatty acid.
  • the medium chain triglyceride is selected from medium-chain triglycerides of the olive oil, coconut oil, or palm kernel oil.
  • the medium chain triglyceride is medium-chain triglycerides of coconut oil.
  • the polyhydric alcohol is selected from ethylene glycol, propylene glycol, hexylene glycol, glycerol, erythritol or sorbitol.
  • the polyhydric alcohol is propylene glycol or hexylene glycol.
  • the ester of fatty acids is selected from higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid.
  • ester of fatty acid is isopropyl myristate.
  • the stable topical composition comprises caprylic /capric triglyceride, propylene glycol or hexylene glycol and isopropyl myristate.
  • the stable topical composition comprising
  • Miconazole and a corticosteroid of the present invention further comprises one or more additional pharmaceutical excipients selected from a group consisting a chelating agent and a preservatives.
  • the chelating agents selected from a group consisting of ethylene diamine tetra-acetic acid (EDTA), disodium edetate and or any combination thereof.
  • the preservatives selected from a group consisting of phenoxyethanol, parabens such as methyl paraben and propyl paraben, propylene glycols, sorbates, benzyl alcohol, butylated hydroxyl toluene, urea derivatives such as diazolindinyl urea, and the like or any combinations thereof.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, l%-20% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 1%-10% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition comprises one or more of 0.5% -2% of Miconazole, 0.01%-1% of a corticosteroid, 30%-80% of caprylic /capric triglyceride, l%-25% of propylene glycol or hexylene glycol, 15%-50% of isopropyl myristate, 0.05%-2% of a preservative and 0.01%-1% of a chelating agent by weight of the composition.
  • the stable topical composition of the present invention may further comprise some additional active agents selected from a group consisting of bacitracin, erythromycin, neomycin, tetracycline, chlortetracycline, benzethonium chloride, phenol, finasteride, ketoconazole, salicylic acid, zinc pyrithione, coal tar, benzoyl peroxide, selenium sulfide, hydrocortisone, sulfur, menthol, pramoxine hydrochloride, tricetylmonium chloride, polyquaternium 10, panthenol, panthenol triacetate, vitamin A and derivatives thereof, vitamin B and derivatives thereof, vitamin C and derivatives thereof, vitamin D and derivatives thereof, vitamin E and derivatives thereof, vitamin K and derivatives thereof, keratin, lysine, arginine, hydrolyzed wheat proteins, hydrolyzed silk proteins, octyl
  • methoxycinnamate oxybenzone
  • minoxidil titanium dioxide, zinc dioxide, retinol, erthromycin, tretinoin, clotrimazole, itraconazole, miconazole, sulconazole, butoconazole, fluconazole, miconazole and mixtures thereof.
  • the stable topical composition of the present invention may further comprise suitable additional excipient include but not limited to acrylamide/ sodium acryloyldimethyl taurate, isohexadecane, polyoxyethylene sorbitan monooleate, sorbitan monostearate, N-methyl-2-pyrrolidone, glycerin, glyceryl monooleate, glyceryl monostearate, polyglyceryl stearate, polyglyceryl myristate, hydrogenated lecithin, diethanolamine cetyl phosphate, diisopropyl adipate, lanolin, lanolin alcohol, hydrogenated lanolin, liquid paraffins, diethanolamine, diisopropanolamine, triethanolamine, acetic acid, citric acid, fumaric acid, lactic acid, malic acid, tartaric acid, Cetomacrogol E wax, polyoxyethyl cetyl ether (Brij 58), butylated hydroxy toluene
  • the stable topical composition of the present invention is in the form of any of the dosage form such as gels, creams, ointments, lotions, shampoo, powders, suspensions and solutions.
  • the stable topical composition of this invention may be used treating fungal infections like dermatophytosis, mucocutaneous candidiasis, Tinea pedis, tinea corporis and tinea cruris; Candidiasis: Intertrigo and interdigital erosion, Tinea versicolor, trichophytosis, vorticosus trichophytosis, tinea profunda, trichomycosis favosa, etc., candidias such as sublimis candidias, profunda candidias, tinea nigra, sporotrichosis, chromomycosis, cryptococcosis, aspergillosis, mucormycosis, coccidioidomycosis, histoplasmosis, erythema mycoticum infantile, intertrigo erosiva candidamycetica, erosio interdigitalis candidamycetica angulus infectious candidamyceticus, chronic mucocutaneous candidia
  • the stable topical composition of the present invention is for use in treating fungal infections.
  • the present invention relates to method of treating fungal infections using stable topical composition of the invention.
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel. Then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve butylated hydroxy toluene and methylparaben in propylene glycol at 60°C-65°C. Add this solution step to step I.
  • Step III Disperse luliconazole in benzyl alcohol and add to step II Physical Parameters:
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel. Then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve propyl paraben and Methylparaben in medium chain triglyceride at 60°C-65°C. Add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene and methylparaben in propylene glycol at 60°C-65°C. Add this solution step to step I.
  • Step IV Dissolve luliconazole in pharmasolve to form a clear solution and add this solution to step III
  • Step I Mix hexylene glycol, medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve Luliconazole in Pharmasolve and add to step I.
  • Step VI Store in a tightly closed container below 30°C.
  • EXAMPLE 4 Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve beclomethasone dipropionate in propylene glycol at 60°C-65°C and add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene, methylparaben and propylparaben in propylene glycol at 60°C-65°C and add this solution step to step II.
  • Step IV Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
  • EXAMPLE 5 Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve beclomethasone dipropionate in in propylene glycol at 60°C- 65 °C and add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene, methylparaben and propylparaben in Propylene glycol at 60°C-65°C and add this solution step to step II.
  • Step IV Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
  • Step V Dissolve triethanolamine in purified water and add to step IV.
  • EXAMPLE 6 Luliconazole and Beclomethasone Dipropionate Cream (1% w/w & 0.025% w/w)
  • Step I Dissolve disodium edetate in purified water, then add under slow stirring Sepineo P600 to get white gel and then add medium chain triglyceride and isopropyl myristate.
  • Step II Dissolve beclomethasone dipropionate in in propylene glycol at 60°C- 65 °C and add this solution step to step I.
  • Step III Dissolve butylated hydroxy toluene, methylparaben and propylparaben in Propylene glycol at 60°C-65°C and add this solution step to step II.
  • Step IV Add and dissolve luliconazole in a mixture of benzyl alcohol and Pharmasolve and add to step III.
  • Step V Dissolve citric acid monohydrate in purified water and add to step IV.
  • EXAMPLE 7 Luliconazole and Beclomethasone Dipropionate Stable topical Solution (Lotion) (1% w/v)
  • Step I Mix hexylene glycol, medium chain triglyceride & isopropyl myristate.
  • Step II Dissolve Beclomethasone Dipropionate and Luliconazole in Pharmasolve and add to step I. Filter through 200# nylon cloth and make up volume with Medium Chain Triglyceride.
  • Step VI Store in a tightly closed container below 30°C.
  • EXAMPLE 8 Luliconazole Stable topical Powder with AUantoin (1% w/w and 0.2% w/w)
  • Step I Weigh accurately maize starch, and dry it at 120°C for 1 hour. Mix Luliconazole, AUantoin with maize starch, talc, mix for properly and shift through 100# sieve.
  • Step II Sift powder perfume passing through 300# sieve and spray and uniformly with I blend and shift the final blend through 40# sieve.
  • EXAMPLE 9 Luliconazole Stable topical Powder with AUantoin (1% w/w and 0.2% w/w)
  • Step I Weigh accurately maize starch, and dry it at 120°C for 1 hour. Mix Luliconazole, AUantoin with maize starch, talc, mix for properly and shift through 100# sieve.
  • Step II Sift powder perfume passing through 300# sieve and spray and mix uniformly with I blend and shift the final blend through 40# sieve.
  • Step I Dissolved citric acid monohydrate, Vancide 89 in purified water. Add gum acacia and allow soaking for 30 minutes. After soaking disperse in selenium sulfide for 30 minutes. Then load bulk to boll mill for 30 minutes.
  • Step II In a separate vessel take, add diethanol amine lauryl sulphate in purified water and heat to 60°C -65°C. Add ethylene glycol stearates under stirring and continue heating till temperature reaches to 70°C-75°C. Then add DELS slowly to avoid precipitation of ethylene glycol stearate. Stir slowly till temperature reaches to 40°C. Then add selenium sulfide slurry in step II.
  • Step III In a separate vessel disperse luliconazole in DELS under stirring for 15 minute and transfer this phase to bulk of step II under slow stirring.
  • Step IV Add glycerol mono ricinoleate to bulk of step III under stirring. Add
  • Step I Add Luliconazole in propylene glycol under stirring to get uniform dispersion. Heat the dispersion to 65°C-70°C to get a clear solution.
  • Step II Add glycerin in step I under stirring to form uniform solution.
  • Step III Make up the volume with propylene glycol and filter the solution through 100# nylon cloth.
  • Step I Add Luliconazole in propylene glycol under stirring to get uniform dispersion. Heat the dispersion to 65°C-70°C to get a clear solution. Add sodium saccharin under stirring to get clear solution.
  • Step II Add glycerin in step I under stirring to form uniform solution. Then add under stirring at 30°C-35°C Aniseed N flavor.
  • Step III Make up the volume with propylene glycol and filter the solution through 100# nylon cloth.
  • Step I Heat cetosteryl alcohol, Arlacel 165, white wax, glyceryl monosterate (NSE), butylated hydroxytolunene, chlorocresol to 65°C -70°C, get clear phase
  • Step II Dissolve sodium citrate anhydrous, citric acid monohydrate in purified water, and propylene glycol, mixture at to 65 °C -70°C.
  • Step III Dissolve luliconazole separately in propylene glycol at to 60°C -65°C
  • Step IV Dissolve clobetasol propionate in in propylene glycol at 50°C-55°C. Add this solution step to step I.
  • Step V Add step I in step II at 65-70°C , emulsify for 5 minutes then add step III at 65°C to emulsification, after mixing add step IV mix well.
  • Step IV Separately dissolve Neomycin sulphate at 40°C to get clear solution in purified water and then add this solution to main bulk at 40°C.
  • EXAMPLE 14 Luliconazole, Clobetasol propionate and Neomycin Sulphate Cream (1% w/w, 0.05% w/w & 0.5%w/w)
  • Step I Dissolve disodium EDTA in purified water at to 70°C -72°C
  • Step II Mix Cetomacrogol E wax, liquid paraffin, glyceryl monosterate (SE), polyoxyethyl cetyl ether (Brij 58), butylated hydroxy toluene, chlorocresol and heat it completely to 70°C -72°C .
  • Step III Ttransfer oil phase to aqueous phase, under homogenization at 70-72°C to form emulsion.
  • Step IV Dissolve clobetasol propionate in in propylene glycol at 50°C-55°C and add this solution to step III.
  • Step V Separately dissolve neomycin sulphate at 40°C to get clear solution.in purified water and then add this solution to step IV at 40°C.
  • Step VI Separately dissolve in it citric acid monohydrate and sodium citrate in purified water to get a clear solution and add this to step V.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions topiques stables comprenant du luliconazole. En outre, la présente invention concerne également des compositions topiques stables comprenant une combinaison de luliconazole avec un corticoïde tel que la bétaméthasone ou le clobétasol. Les compositions sont exemptes d'alcool aliphatique et de cétone.
PCT/IB2017/053078 2016-05-25 2017-05-25 Compositions topiques stables de luliconazole WO2017203456A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR112018074143-4A BR112018074143A2 (pt) 2016-05-25 2017-05-25 composição tópica estável e método de tratamento de infecções fúngicas
RU2018141796A RU2018141796A (ru) 2016-05-25 2017-05-25 Стабильные композиции луликоназола для местного применения
MX2018014485A MX2018014485A (es) 2016-05-25 2017-05-25 Composiciones topicas estables de luliconazol.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621017933 2016-05-25
IN201621017933 2016-05-25

Publications (1)

Publication Number Publication Date
WO2017203456A1 true WO2017203456A1 (fr) 2017-11-30

Family

ID=60411128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/053078 WO2017203456A1 (fr) 2016-05-25 2017-05-25 Compositions topiques stables de luliconazole

Country Status (4)

Country Link
BR (1) BR112018074143A2 (fr)
MX (1) MX2018014485A (fr)
RU (1) RU2018141796A (fr)
WO (1) WO2017203456A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216722A3 (fr) * 2016-06-13 2018-03-01 Vyome Biosciences Pvt. Ltd. Compositions antifongiques synergiques et leurs procédés
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition
RU2806765C2 (ru) * 2018-03-19 2023-11-07 ЭмСи2 ТЕРАПЬЮТИКС ЛИМИТЕД Композиция для местного применения

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231379A1 (en) * 2007-08-27 2013-09-05 Nihon Nohyaku Co., Ltd. Agent for fungal dermatitis
WO2014042043A9 (fr) * 2012-09-14 2015-05-21 Pola Pharma Inc. Composition pharmaceutique contenant du luliconazole
WO2015156219A1 (fr) * 2014-04-07 2015-10-15 日本農薬株式会社 Composition pharmaceutique comprenant un agent anti-fongique et un stéroïde

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231379A1 (en) * 2007-08-27 2013-09-05 Nihon Nohyaku Co., Ltd. Agent for fungal dermatitis
WO2014042043A9 (fr) * 2012-09-14 2015-05-21 Pola Pharma Inc. Composition pharmaceutique contenant du luliconazole
WO2015156219A1 (fr) * 2014-04-07 2015-10-15 日本農薬株式会社 Composition pharmaceutique comprenant un agent anti-fongique et un stéroïde

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216722A3 (fr) * 2016-06-13 2018-03-01 Vyome Biosciences Pvt. Ltd. Compositions antifongiques synergiques et leurs procédés
US11696919B2 (en) 2018-03-19 2023-07-11 MC2 Therapeutics Limited Topical composition
RU2806765C2 (ru) * 2018-03-19 2023-11-07 ЭмСи2 ТЕРАПЬЮТИКС ЛИМИТЕД Композиция для местного применения

Also Published As

Publication number Publication date
RU2018141796A (ru) 2020-06-25
MX2018014485A (es) 2019-08-12
RU2018141796A3 (fr) 2020-08-27
BR112018074143A2 (pt) 2019-04-16

Similar Documents

Publication Publication Date Title
US20100048598A1 (en) Topical compositions comprising 5-alpha reductase inhibitors
US8835410B2 (en) Treatment of eyelid dermatitis
JP6666068B2 (ja) 外用組成物
US9855334B2 (en) Topical compositions comprising a corticosteroid
JP2016515525A (ja) フルニソリドの局所用組成物および治療方法
EP3677265A1 (fr) Composition pour prévenir ou traiter les troubles du sommeil
WO2017203456A1 (fr) Compositions topiques stables de luliconazole
CA3023259A1 (fr) Compositions et methodes pour le traitement de l'inflammation ou de l'infection de l'oeil
JP2019501861A (ja) 水不溶性またはわずかに水溶性の薬剤の水可溶性を改善するための方法
EP2303281B1 (fr) Compositions pharmaceutiques transdermiques renfermant du danazol
JP2022160648A (ja) フェノルドパムの安定な局所用組成物
US11642309B2 (en) Aqueous compositions comprising bilastine and mometasone
US20230181555A1 (en) Stable and preserved pharmaceutical compositions of bilastine
US11957669B2 (en) Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
US20090253712A1 (en) Aqueous solvent system for solubilization of azole compounds
WO2007086582A1 (fr) LOTION EN ÉMULSION DE TYPE HUILE DANS L'EAU CONTENANT DE LA 22-OXA-1α,25-DIHYDROXYVITAMINE D3 ET MÉTHODE DE TRAITEMENT D'UNE MALADIE CUTANÉE UTILISANT LADITE LOTION
JP2005350379A (ja) 吉草酸酢酸プレドニゾロンを安定化させる方法及び安定性に優れた吉草酸酢酸プレドニゾロン配合皮膚外用剤
BR112019016545A2 (pt) Composição para administração intravesical para tratamento de dor na bexiga
JP5460766B2 (ja) 外用医薬組成物
JP2007230957A (ja) トラニラストまたはその薬理学的に許容される塩を含有する懸濁性医薬組成物
TW200418516A (en) Droplet dispersed ointment
WO2024063712A1 (fr) Compositions pharmaceutiques comprenant du chlorhydrate d'azélastine, du propionate de fluticasone et des excipients pertinents
KR20150128952A (ko) 플루니솔리드의 국소 조성물 및 치료 방법

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17802295

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018074143

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112018074143

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181123

122 Ep: pct application non-entry in european phase

Ref document number: 17802295

Country of ref document: EP

Kind code of ref document: A1